ASP1707治疗子宫内膜异位症相关盆腔痛的疗效与安全性:II期随机对照TERRA研究
这项II期多中心双盲随机安慰剂对照研究纳入540例子宫内膜异位症相关盆腔痛女性,评估GnRH拮抗剂ASP1707(3、5、10、15 mg)与亮丙瑞林相比的疗效与安全性。治疗12周后,ASP1707各剂量组在总体盆腔痛、痛经和非经期盆腔痛的数字评分改善上呈显著剂量相关效应,且血清雌二醇和骨密度下降程度轻于亮丙瑞林。
要点
- ASP1707各剂量在治疗12周后对总体盆腔痛、痛经和非经期盆腔痛的改善呈显著剂量相关效应(P=0.001、P<0.001、P=0.029)。
- ASP1707各剂量使血清雌二醇和骨密度呈剂量依赖性下降,但降幅小于亮丙瑞林。
- 本研究未针对各ASP1707剂量组与安慰剂组的成对比较进行效能计算。
核心结论
- ASP1707以剂量相关方式显著减轻子宫内膜异位症相关盆腔痛。
- ASP1707各剂量使血清雌二醇降至目标范围内,且降幅小于亮丙瑞林;作者认为ASP1707是亮丙瑞林治疗子宫内膜异位症相关盆腔痛的潜在替代方案,对骨健康影响更小。
研究设计与样本
- II期、多中心、双盲、随机、平行组、安慰剂对照研究,于2012年12月4日至2015年7月30日在欧洲和日本开展。
- 共筛查912例子宫内膜异位症相关盆腔痛女性,入组540例,532例接受至少1次研究药物(安慰剂n=88;ASP1707 3 mg n=86;5 mg n=91;10 mg n=90;15 mg n=88;亮丙瑞林n=89),治疗24周。
- 样本量计算为504例(每组84例),以在假设不同剂量反应曲线条件下提供≥80%效能检测12周治疗后盆腔痛自基线的剂量相关治疗效应。
主要发现
- 治疗12周后,总体盆腔痛NRS均值(95%CI)变化:安慰剂-1.56(-1.91,-1.21),ASP1707 3 mg -1.63(-1.99,-1.27),5 mg -1.93(-2.27,-1.60),10 mg -2.29(-2.64,-1.94),15 mg -2.13(-2.47,-1.79)。
- 治疗12周后,痛经NRS均值(95%CI)变化:安慰剂-1.50(-2.00,-1.00),ASP1707 3 mg -2.72(-3.22,-2.21),5 mg -2.85(-3.33,-2.38),10 mg -3.97(-4.46,-3.48),15 mg -4.18(-4.66,-3.70)。
- 治疗12周后,非经期盆腔痛NRS均值(95%CI)变化:安慰剂-1.53(-1.88,-1.19),ASP1707 3 mg -1.51(-1.87,-1.16),5 mg -1.80(-2.14,-1.47),10 mg -2.03(-2.37,-1.68),15 mg -1.86(-2.20,-1.52)。
- 治疗12周后,ASP1707各剂量间总体盆腔痛(P=0.001)、痛经(P<0.001)和非经期盆腔痛(P=0.029)的NRS下降呈统计学显著剂量相关治疗效应,并维持至24周。
- 血清雌二醇和骨密度随ASP1707治疗至24周呈剂量依赖性下降,但降幅小于亮丙瑞林。
临床怎么用
- 原文未据此给出临床推荐;作者认为ASP1707是亮丙瑞林治疗子宫内膜异位症相关盆腔痛的潜在替代方案,对骨健康影响更小。
局限性
- 本研究未针对各ASP1707剂量组与安慰剂组的成对比较进行效能计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does the GnRH antagonist, ASP1707, reduce endometriosis-associated pelvic pain? SUMMARY ANSWER: ASP1707 significantly reduced endometriosis-associated pelvic pain in a dose-related manner. WHAT IS KNOWN ALREADY: GnRH agonists are an effective therapeutic option for endometriosis that is refractory to non-steroidal anti-inflammatory drugs, oral contraceptives, and progestins. However, GnRH agonists cause complete suppression of estradiol (E2), resulting in hypoestrogenic side-effects such as bone loss that may increase the future risk of osteoporotic fractures. STUDY DESIGN, SIZE, DURATION: This was a Phase II, multicenter, double-blind, randomized, parallel-group, placebo-controlled study conducted in 540 women from 04 December 2012 to 30 July 2015 in Europe and Japan. A sample size of 504 (84 subjects per group) was calculated to provide ≥80% power to detect a dose-related treatment effect among placebo and ASP1707 doses in change from baseline in pelvic pain, assuming different dose-response curves after 12 weeks of treatment. PARTICIPANTS/MATERIALS, SETTING, METHODS: Of 912 women with endometriosis-associated pelvic pain screened, 540 were enrolled, and 532 received ≥1 dose of study drug (placebo, n = 88; ASP1707 3 mg, n = 86; ASP1707 5 mg, n = 91; ASP1707 10 mg, n = 90; ASP1707 15 mg, n = 88; leuprorelin, n = 89) for 24 weeks. MAIN RESULTS AND THE ROLE OF CHANCE: After 12 weeks of treatment with ASP1707, the mean (95% CI) changes in numeric rating score (NRS) for overall pelvic pain (OPP) were -1.56 (-1.91, -1.21), -1.63 (-1.99, -1.27), -1.93 (-2.27, -1.60), -2.29 (-2.64, -1.94), and -2.13 (-2.47, -1.79) for placebo, ASP1707 3 mg, ASP1707 5 mg, ASP1707 10 mg, and ASP1707 15 mg, respectively. Mean (95% CI) changes in NRS for dysmenorrhea were -1.50 (-2.00, -1.00), -2.72 (-3.22, -2.21), -2.85 (-3.33, -2.38), -3.97 (-4.46, -3.48), and -4.18 (-4.66, -3.70), respectively. Mean (95% CI) changes in NRS for non-menstrual pelvic pain (NMPP) were -1.53 (-1.88, -1.19), -1.51 (-1.87, -1.16), -1.80 (-2.14, -1.47), -2.03 (-2.37, -1.68), and -1.86 (-2.20, -1.52), respectively. Statistically significant dose-related treatment effects in reduction in NRS for OPP (P = 0.001), dysmenorrhea (P < 0.001), and NMPP (P = 0.029) were observed after 12 weeks among ASP1707 doses and were maintained through 24 weeks. Serum estradiol and bone mineral density decreased dose dependently with ASP1707 through 24 weeks, however, to a lesser extent than with leuprorelin. LIMITATIONS, REASON FOR CAUTION: This study was not powered for pairwise comparison of each ASP1707 group versus placebo. WIDER IMPLICATIONS OF THE FINDINGS: All doses of ASP1707 reduced serum E2 levels to within the target range and to a lesser extent than leuprorelin. ASP1707 is a potential alternative treatment to leuprorelin for endometriosis-associated pelvic pain with lower impact on bone health. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by Astellas Pharma Inc. T.D'.H is Vice President and Head of Global Medical Affairs Fertility at Merck, Darmstadt, Germany since October 1, 2015. At the time that the TERRA study was conducted, he served as Principal Investigator in his role as Coordinator of the Leuven University Fertility Center. Since October 2015, T.D'.H has left Leuven University Hospital Gasthuisberg, but continues to serve as Professor in Reproductive Medicine and Biology at KU Leuven (University of Leuven) Belgium and at the Dept of Obstetrics, Gynecology and Reproduction at Yale University, New Haven, USA. T. Fukaya and Y. Osuga report personal consulting fees from Astellas Pharma Inc. during the conduct of the study and outside the submitted work. G.M. Holtkamp, and L. Skillern are employed by Astellas Pharma Europe B.V.; K. Miyazaki is employed by Astellas Pharma Inc.; B. López, was a biostatistician for Astellas Pharma Europe B.V. during conduct of the study; R. Besuyen was a contract Associate Director of Medical Science for Astellas during conduct of the study. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, www.clinicaltrials.gov, NCT01767090. EudraCT number 2012-002791-14. TRIAL REGISTRATION DATE: 18 December 2012. DATE OF FIRST SUBJECT’S ENROLLMENT: One subject signed informed consent on 04 December 2012; the first subject was randomized on 16 April 2013.
引用
- D'Hooghe T, Fukaya T, Osuga Y, et al. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study. Hum Reprod. 2019. PMID: 31067329. doi:10.1093/humrep/dez028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。